椎管内分娩镇痛与阴道助产后新生儿发病率的相关性
基于美国2017年出生证明数据的横断面研究,纳入106,845例阴道助产分娩产妇,其中86.6%接受椎管内分娩镇痛。椎管内镇痛组新生儿发病率高于非椎管内组(11.3% vs 8.9%,P<0.001),校正后相对风险为1.19(95%CI 1.12–1.26;P<0.001),未观察到椎管内分娩镇痛对阴道助产后新生儿的保护效应。
要点
- 阴道助产后接受椎管内分娩镇痛者新生儿发病率更高,校正混杂后aRR为1.19。
- 去除NICU入住和新生儿转运后复合结局无统计学意义(aRR 1.07,P=0.054)。
- 适应证混杂可能解释该关联,该数据集无法评估此问题。
核心结论
- 在阴道助产分娩人群中,未观察到椎管内分娩镇痛对新生儿发病率的保护效应。
- 观察到的椎管内镇痛与新生儿发病率之间的关联可能由适应证混杂解释,但该数据集并非为评估此类问题而设计。
研究设计与样本
- 基于美国出生证明数据的 population-based 横断面研究。
- 纳入2017年单胎妊娠并经产钳或胎吸助产分娩的产妇106,845例。
- 暴露为椎管内分娩镇痛,主要结局为复合新生儿发病率。
- 分析中校正社会人口学和产科因素作为潜在混杂因素。
主要发现
- 106,845例产妇中92,518例(86.6%)接受椎管内分娩镇痛。
- 椎管内镇痛组新生儿发病率高于非椎管内组(10,409/92,518 [11.3%] vs 1,271/14,327 [8.9%],P<0.001)。
- 未校正相对风险为1.27(95%CI 1.20–1.34;P<0.001)。
- 多变量模型校正混杂后相对风险为1.19(95%CI 1.12–1.26;P<0.001)。
- 事后分析排除NICU入住和新生儿转运后,椎管内镇痛对新生儿发病率的影响无统计学意义(校正相对风险1.07;95%CI 1.00–1.16;P=0.054)。
临床怎么用
- 阴道助产前评估椎管内分娩镇痛时,应结合产科指征和新生儿风险综合权衡。
- 该研究提示椎管内镇痛不降低阴道助产后新生儿发病率,临床决策不应以新生儿获益为依据。
- 对阴道助产产妇的新生儿应加强监测,尤其关注Apgar评分、呼吸支持和NICU入住等指标。
局限性
- 研究为观察性横断面设计,无法排除适应证混杂。
- 该数据集并非为评估适应证混杂而设计。
- 复合结局中NICU入住和新生儿转运对结果影响较大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 84% of women who undergo operative vaginal delivery receive neuraxial analgesia. However, little is known about the association between neuraxial analgesia and neonatal morbidity in women who undergo operative vaginal delivery. The authors hypothesized that neuraxial analgesia is associated with a reduced risk of neonatal morbidity among women undergoing operative vaginal delivery. METHODS: Using United States birth certificate data, the study identified women with singleton pregnancies who underwent operative vaginal (forceps- or vacuum-assisted delivery) in 2017. The authors examined the relationships between neuraxial labor analgesia and neonatal morbidity, the latter defined by any of the following: 5-min Apgar score less than 7, immediate assisted ventilation, assisted ventilation greater than 6 h, neonatal intensive care unit admission, neonatal transfer to a different facility within 24 h of delivery, and neonatal seizure or serious neurologic dysfunction. The authors accounted for sociodemographic and obstetric factors as potential confounders in their analysis. RESULTS: The study cohort comprised 106,845 women who underwent operative vaginal delivery, of whom 92,518 (86.6%) received neuraxial analgesia. The proportion of neonates with morbidity was higher in the neuraxial analgesia group than the nonneuraxial group (10,409 of 92,518 [11.3%] vs. 1,271 of 14,327 [8.9%], respectively; P < 0.001). The unadjusted relative risk was 1.27 (95% CI, 1.20 to 1.34; P < 0.001); after accounting for confounders using a multivariable model, the adjusted relative risk was 1.19 (95% CI, 1.12 to 1.26; P < 0.001). In a post hoc analysis, after excluding neonatal intensive care unit admission and neonatal transfer from the composite outcome, the effect of neuraxial analgesia on neonatal morbidity was not statistically significant (adjusted relative risk, 1.07; 95% CI, 1.00 to 1.16; P = 0.054). CONCLUSIONS: In this population-based cross-sectional study, a neonatal benefit of neuraxial analgesia for operative vaginal delivery was not observed. Confounding by indication may explain the observed association between neuraxial analgesia and neonatal morbidity, however this dataset was not designed to evaluate such considerations.
引用
- Butwick AJ, Wong CA, Lee HC, et al. Association between Neuraxial Labor Analgesia and Neonatal Morbidity after Operative Vaginal Delivery. Anesthesiology. 2021. PMID: 33045040. doi:10.1097/ALN.0000000000003589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。